A Study to Investigate the Metabolism and Excretion of [14C]-TRV130 in Healthy Male Subjects

This study is an open-label, non-randomized, metabolism and excretion study of a single 2 mg IV dose of [14C] TRV130 (approximately 100 µCi) administered as a 10 mL manual IV push over 2 minutes in a fasted state.

Key Inclusion Criteria:

• Males, between 18 and 64 years of age, inclusive
• With body weight ≥ 50 kg and body mass index (BMI) between 18 and 32 kg/m2, inclusive
• In good health, determined by no clinically significant findings from medical history, 12-lead ECG, and vital signs
• Negative test for selected drugs of abuse at Screening and at Check-in
• Able to comprehend and willing to sign an Informed Consent Form (ICF) prior to any study procedure
• A typical minimum of 1 to 2 bowel movements per day

Key Exclusion Criteria:

• History of sensitivity to any of the study medications or components thereof or a history of medication or other allergy that, in the opinion of the Investigator, contraindicates their participation
• Participation in any other investigational study drug trial in which receipt of an investigational study drug occurred within 28 days prior to Check-in
• Participation in any other radiolabeled investigational study drug trial within 12 months prior to Check-in
• Exposure to significant radiation (eg, serial x-ray or computed tomography scans, barium meal, current employment in a job requiring radiation exposure monitoring) within 12 months prior to Check-in
• Has current malignancy, current systemic chemotherapy, or cancer diagnosis within 5 years prior to Screening (excluding squamous or basal cell carcinoma of the skin that has been clinically stable and fully excised in a curative procedure);
• Use of any tobacco- or nicotine-containing products within 6 months prior to Screening